Gilead Sciences' (GILD) "Outperform" Rating Reaffirmed at Oppenheimer

Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "outperform" rating reissued by equities research analysts at Oppenheimer in a research note issued on Friday, Benzinga reports. They presently have a $105.00 target price on the biopharmaceutical company's stock. Oppenheimer's target price points to a potential upside of 57.28% from the stock's current price.

A number of other analysts have also issued reports on GILD. Royal Bank of Canada cut their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a "sector perform" rating on the stock in a research note on Wednesday, February 14th. Barclays cut their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday, February 12th. UBS Group cut their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a "neutral" rating on the stock in a research note on Wednesday. Mizuho cut their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, February 22nd. Finally, Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Hold" and a consensus price target of $84.71.

Gilead Sciences Trading Up 0.9 %

Shares of NASDAQ GILD traded up $0.60 during trading on Friday, hitting $66.76. 10,656,822 shares of the company were exchanged, compared to its average volume of 7,352,068. The firm has a market capitalization of $83.12 billion, a PE ratio of 14.84, a P/E/G ratio of 0.92 and a beta of 0.19. Gilead Sciences has a 12-month low of $65.90 and a 12-month high of $87.86. The company has a fifty day moving average price of $71.96 and a 200-day moving average price of $76.53. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts' expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 earnings per share. As a group, equities research analysts expect that Gilead Sciences will post 6.55 EPS for the current year.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares of the company's stock, valued at $7,386,496.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the company. PCA Investment Advisory Services Inc. purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $25,000. Tompkins Financial Corp raised its stake in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. OFI Invest Asset Management purchased a new stake in shares of Gilead Sciences during the third quarter worth approximately $26,000. Finally, Fortitude Family Office LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.